CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Trial of Erlotinib and Onalespib Lactate in EGFR-Mutant Non-Small Cell Lung Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02535338
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:47.400689+00:00
Published At: 2022-06-22T00:00:00+00:00
Record Updated At: 2025-03-03
Results Posted At: 2022-06-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Recurrent Lung Non-Small Cell Carcinoma", "Stage IV Lung Non-Small Cell Cancer AJCC v7"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-03-03"
protocolSection.identificationModule.nctId: "NCT02535338"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Trial of Erlotinib and Onalespib Lactate in EGFR-Mutant Non-Small Cell Lung Cancer"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2022-06-22"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.